Genome-editing in millets: current knowledge and future perspectives

Author(s):  
Antony Ceasar
Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1266
Author(s):  
Andreja Figurek ◽  
Merita Rroji ◽  
Goce Spasovski

Fibroblast growth factor-23 (FGF23) appears to be one of the most promising biomarkers and predictors of cardiovascular risk in patients with heart disease and normal kidney function, but moreover in those with chronic kidney disease (CKD). This review summarizes the current knowledge of FGF23 mechanisms of action in the myocardium in the physiological and pathophysiological state of CKD, as well as its cross-talk to other important signaling pathways in cardiomyocytes. In this regard, current therapeutic possibilities and future perspectives are also discussed.


2021 ◽  
pp. 103753
Author(s):  
Qiaomin Pei ◽  
Eri Saikawa ◽  
Susan Kaspari ◽  
David Widory ◽  
Chuanfeng Zhao ◽  
...  

2018 ◽  
Vol 7 (4) ◽  
pp. 38 ◽  
Author(s):  
Valeria D’Argenio

The last few years have featured an increasing interest in the study of the human microbiome and its correlations with health status. Indeed, technological advances have allowed the study of microbial communities to reach a previously unthinkable sensitivity, showing the presence of microbes also in environments usually considered as sterile. In this scenario, microbial communities have been described in the amniotic fluid, the umbilical blood cord, and the placenta, denying a dogma of reproductive medicine that considers the uterus like a sterile womb. This prenatal microbiome may play a role not only in fetal development but also in the predisposition to diseases that may develop later in life, and also in adulthood. Thus, the aim of this review is to report the current knowledge regarding the prenatal microbiome composition, its association with pathological processes, and the future perspectives regarding its manipulation for healthy status promotion and maintenance.


Sign in / Sign up

Export Citation Format

Share Document